Reduced effectiveness of long-term interferon-β treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study

Abstract

Multiple sclerosis (MS) patients treated with interferon-beta (IFN-β) often form anti-IFN-β antibodies accompanied by a reduction in IFN-β bioavailability. The clinical effect of these antibodies remains controversial. MS patients in British Columbia, Canada, must be diagnosed and evaluated annually by neurologists in an MS clinic in order to be reimbursed for their IFN-β prescriptions. We have identified at the UBC MS clinic a cohort of 262 patients, each having been treated with a single IFN-β preparation more than three years, some for nearly a decade. Of 119 patients treated with Betaseron^® (IFN-β1b), 18 (15.1%) were neutralizing antibody positive (NAb+) at the time of the study, whereas of 131 treated with subcutaneous Rebif^® (IFN-β1a SC), 16 (12.2%) were NAb+, but none of 12 treated with intramuscular Avonex^® (IFN-β1a) had detectable neutralizing antibodies. During the first two years of treatment, the relapse rate was significantly reduced from pre-treatment rates (P < 0.001) and appeared to be unaffected by the subsequent NAb status. However, the relapse rates in the NAb+ patients were significantly greater than in the NAb— patients during years 3 (P < 0.010) and 4 (P < 0.027). Betaseron ^® -treated NAb+ patients tended to have more relapses than NAb— patients during year 3 and this almost reached significance (P = 0.056) but their relapse rate did not differ in year 4 and later. In contrast, Rebif ^® -treated NAb+ patients tended to have more relapses in year 3 than Rebif ^® -treated NAb— patients (P = 0.074), but in year 4 they clearly (P = 0.009) had more relapses than Rebif ^® -treated NAb— patients. There was no convincing effect on progression of disability in any group. Multiple Sclerosis 2007; 13: 1127—1137. http://msj.sagepub.com

Keywords

binding antibody interferon-beta multiple sclerosis neutralizing antibody relapse rates

Get full access to this article

View all access options for this article.

References

Prisms. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS . Neurology 2001; 56: 1628—36 .

The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years . Neurology 1996; 47: 889—94 .

Larocca AP , Leung SC , Marcus SG , Colby CB , Borden EC Evaluation of neutralizing antibodies in patients treated with recombinant interferon-beta ser . J Interferon Res 1989 ; 9(Suppl 1): S51—S60 .

Oger J. , Roos R. , Antel JP Immunology of multiple sclerosis . Neurol Clin 1983; 1: 655—79 .

Antonelli G. , Bagnato F. , Pozzilli C. , Simeoni E. , Bastianelli S. , Currenti M. et al. Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-beta1a . J Interferon Cytokine Res 1998; 18: 345—50 .

Ross C. , Clemmesen KM , Svenson M. , Sorensen PS , Koch-Henriksen N. , Skovgaard GL et al. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group . Ann Neurol 2000; 48: 706—12 .

Redlich PN , Hoeprich PD, Jr. , Colby CB , Grossberg SE Antibodies that neutralize human beta interferon biologic activity recognize a linear epitope: analysis by synthetic peptide mapping . Proc Natl Acad Sci USA 1991; 88: 4040—4 .

Runkel L. , deDios C. , Karpusas M. , Baker D. , Li Z. , Zafari M. et al. Mapping of interferon-β epitopes important for receptor binding and activation: comparison of results achieved using antibody-based methods and alanine substitution mutagenesis . J Interferon Cytokine Res 2001; 21: 931—41 .

Bertolotto A. , Gilli F. , Sala A. , Capobianco M. , Malucchi S. , Milano E. et al. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients . Neurology 2003; 60: 634—9 .

10.

Deisenhammer F. , Reindl M. , Harvey J. , Gasse T. , Dilitz E. , Berger T. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies . Neurology 1999; 52: 1239—43 .

11.

Malucchi S. , Sala A. , Gilli F. , Bottero R. , Di Sapio A. , Capobianco M. et al. Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis . Neurology 2004; 62: 2031—7 .

12.

Rudick RA , Simonian NA , Alam JA , Campion M. , Scaramucci JO , Jones W. et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG) . Neurology 1998; 50: 1266—72 .

13.

Sorensen PS , Ross C. , Clemmesen KM , Bendtzen K. , Frederiksen JL , Jensen K. et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis . Lancet 2003; 362: 1184—91 .

14.

Vallittu AM , Halminen M. , Peltoniemi J. , Ilonen J. , Julkunen I. , Salmi A. et al. Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients . Neurology 2002; 58: 1786—90 .

15.

Pachner A. , Narayan K. , Price N. , Hurd M. , Dail D. MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity . Mol Diagn 2003; 7: 17—25 .

16.

Pachner AR , Oger J. , Palace J. The measurement of antibodies binding to IFNbeta in MS patients treated with IFNbeta . Neurology 2003; 61: S18—20 .

17.

Perini P. , Calabrese M. , Biasi G. , Gallo P. The clinical impact of interferon beta antibodies in relapsing-remitting MS . J Neurol 2004; 251: 305—9 .

18.

The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial . Neurology 1995; 45: 1277—85 .

19.

Francis GS , Rice GP , Alsop JC Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS . Neurology 2005; 65: 48—55 .

20.

Rice GP , Paszner B. , Oger J. , Lesaux J. , Paty D. , Ebers G. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b . Neurology 1999; 52: 1277—9 .

21.

Tremlett HL , Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS . Neurology 2003; 61: 551—4 .

22.

Grossberg SE , Taylor JL , Siebenlist RE , Jameson P. Biological and immunological assays of human interferons. In Manual of Clinical Immunology, third edition. Washington, DC: ASM Publishing , 1986, pp 295—9.

23.

Grossberg SE , Kawade Y. , Kohase M. , Yokoyama H. , Finter N. The neutralization of interferons by antibody. I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems . J Interferon Cytokine Res 2001; 21: 729—42 .

24.

Grossberg SE , Kawade Y. , Kohase M. , Klein JP The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit . J Interferon Cytokine Res 2001; 21: 743—55 .

25.

Sorensen PS , Deisenhammer F. , Douda P. , Hohlfeld R. , Myhr K-M. , Palace J. et al. Guidelines on use of anti-IFN-β antibodies in multiple sclerosis . Eur J Neurol 2005; 12: 817—27 .

26.

Gibbs E. , Oger J. Suggested limits for high and low neutralizing antibody levels in interferon-beta treated multiple sclerosis patients . Mult Scler 2006; 12: S204 .

27.

Polman C. , Kappos L. , White R. , Dahlke F. , Beckmann K. , Pozzilli C. et al. Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b . Neurology 2003 ; 60: 37—43 .

28.

PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis . Lancet 1998; 352: 1498—504 .

29.

Sorensen PS , Koch-Henriksen N. , Ross C. , Clemmesen KM , Bendtzen K. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy . Neurology 2005; 65: 33—9 .

30.

Oger J. , Vorobeychick G. , Paty DW In Betaseron®treated MS patients, in vitro immune function can be a predictor of neutralizing antibody development . Neurology 1997; 48: A80 (Abstract).

31.

Petkau AJ , White RA , Ebers GC , Reder AT , Sibley WA , Lublin FD et al. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis . Mult Scler 2004; 10: 126—38 .